# Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

> **NCT04620603** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Case Comprehensive Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Cutaneous Malignant Melanoma
- Renal Cell Cancer
- Urothelial Cancer of Renal Pelvis

## Interventions

- **RADIATION:** Low Dose Rate Brachytherapy (LDR)
- **DRUG:** Standard-of-Care Immunotherapy

## Key facts

- **NCT ID:** NCT04620603
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-27
- **Primary completion:** 2024-03-20
- **Final completion:** 2026-09-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620603, "Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04620603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*